PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 21 PubMed articles · model: gemma4:31b
Summary
Background
Active compounds
Mechanism of action
Clinical evidence
E. polybractea essential oils exhibited high antimicrobial activity, inhibiting or killing most microorganisms at concentrations between 0.25% and 8.0% (v/v) [PMID: 30513933].
A combination of E. polybractea, Ormenis mixta, and Lavandula burnatii essential oils was optimized for antibacterial activity [PMID: 37645561].
Interactions between E. polybractea oil and monofloral honeys (marri and manuka) were found to be additive or indifferent [PMID: 36028831].
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 30513933 (2018) — Antimicrobial Activity of Several Cineole-Rich Western Australian Eucalyptus Essential Oils. · Microorganisms
- 2.PMID: 33219374 (2021) — Monoterpene synthases responsible for the terpene profile of anther glands in Eucalyptus polybractea R.T. Baker (Myrtaceae). · Tree physiology
- 3.PMID: 11159812 (2001) — Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes. · Drug metabolism and disposition: the biological fate of chemicals
- 4.PMID: 37645561 (2023) — Combination of Chemically-Characterized Essential Oils from Eucalyptus polybractea, Ormenis mixta, and Lavandula burnatii: Optimization of a New Complete Antibacterial Formulation Using Simplex-Centroid Mixture Design. · Advances in pharmacological and pharmaceutical sciences
- 5.PMID: 29891736